Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis

A systematic review of the literature was conducted to identify randomized trials involving continuous dopaminergic stimulation (CDS) in PD patients with motor complications. Difference between n groups was assessed by partitioning heterogeneity and using the χ2 distribution with n-1 degrees of freedom, where n equals the number of groups. We looked for publication bias using funnel plotting, Egger's test and Begg's test. Twenty Randomized Controlled Trials (RCTs) were included. The results showed that CDS could evidently improve the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (p < 0.0001), part III (P < 0.00001) and UPDRS total score (p < 0.00001). There was also a statistical discrepancy in off time reduction (p < 0.00001) and prolongation of on time (p < 0.00001) by the CDS therapy compared with control groups. Meanwhile, the results of this study showed obvious side effects in the CDS therapy compared with the placebo, especially at the expense of increased dyskinesia (23.4% vs 11.7%). The present study showed that CDS was beneficial in the treatment of PD patients with motor complications. But the incidence of the side events is more common than placebo.

[1]  M. Guttman.  Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. , 1997, Neurology.

[2]  M. Muenter,et al.  Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease , 1996, Neurology.

[3]  W. Oertel,et al.  Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial , 2005, Movement disorders : official journal of the Movement Disorder Society.

[4]  S. Meunier,et al.  Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease. , 2012, Brain : a journal of neurology.

[5]  Y. Mizuno,et al.  Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study , 1985, Acta neurologica Scandinavica.

[6]  A. Yashin,et al.  Age Patterns of Incidence of Geriatric Disease in the U.S. Elderly Population: Medicare‐Based Analysis , 2012, Journal of the American Geriatrics Society.

[7]  Jia-Guo Zhao.  Identifying and measuring heterogeneity across the studies in meta-analysis. , 2013, The Journal of hand surgery.

[8]  J. Obeso,et al.  Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. , 2000, Neurology.

[9]  S. Fahn,et al.  A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease , 1998, Neurology.

[10]  P. Deyn,et al.  Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care , 2013, Journal of Neural Transmission.

[11]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[12]  Murat Emre,et al.  Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Guttman.  Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease , 1997, Neurology.

[14]  E. Tolosa,et al.  Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.

[15]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[16]  A. Grace.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[17]  O. Rascol,et al.  Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease , 2009, European Neurology.

[18]  P. Jenner,et al.  Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus) , 2003, Experimental Neurology.

[19]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[20]  F. Stocchi.  Continuous dopaminergic stimulation and novel formulations of dopamine agonists , 2011, Journal of Neurology.

[21]  J. Jankovic,et al.  A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease , 1994 .

[22]  L. Wermuth.  A double‐blind, placebo‐controlled, randomized, multi‐center study of pramipexole in advanced Parkinson's disease , 1998, European journal of neurology.

[23]  O. Rascol,et al.  Extended-release pramipexole in advanced Parkinson disease , 2011, Neurology.

[24]  T. Chase,et al.  Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates , 2005, Experimental Neurology.

[25]  B. Bloem,et al.  The treatment of early Parkinson's disease: levodopa rehabilitated , 2011, Practical Neurology.

[26]  F. Stocchi.  The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. , 2009, Parkinsonism & related disorders.

[27]  Jonathan J Shuster,et al.  Rebuttal to Carpenter et al. comments on ‘Fixed vs. random effects meta‐analysis in rare event studies: The rosiglitazone link with myocardial infarction and cardiac death’ , 2008, Statistics in medicine.

[28]  T. Dall,et al.  The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.

[29]  Paul Greengard,et al.  Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.

[30]  C. Olanow,et al.  Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. , 2002, Brain : a journal of neurology.

[31]  J. Jankovic,et al.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.

[32]  Fabrizio Stocchi,et al.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.

[33]  K. Lyons,et al.  Ropinirole 24-hour prolonged release , 2007, Neurology.

[34]  M. Pinter,et al.  Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study , 1999, Journal of neurology, neurosurgery, and psychiatry.

[35]  S. Fahn,et al.  Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.

[36]  P. Jenner,et al.  Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression , 2011, Journal of Neural Transmission.

[37]  C. Waters,et al.  Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease , 2013, Expert review of neurotherapeutics.

[38]  A. Lieberman,et al.  Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study , 1997, Neurology.

[39]  David Seidel,et al.  A systematic review of the worldwide prevalence and incidence of Parkinson's disease. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[40]  K. Chaudhuri,et al.  Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.

[41]  C. Marsden,et al.  Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations , 2004, Journal of Neurology.

[42]  A. Rajput.  Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson's Disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[43]  K. Lyons,et al.  Advanced Parkinson disease treated with rotigotine transdermal system , 2007, Neurology.

[44]  O. Rascol,et al.  Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. , 1996, Clinical neuropharmacology.

[45]  J. Obeso,et al.  Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease , 2006, Nature Clinical Practice Neurology.